V GO NORTE INTERNATIONAL GU DEBATES

8th-9th OCTOBER 2026

#GonorteGUDebates

VENUE

PARADOR DE LIMPIAS
Fuente del Amor s/n,
39820, Limpias (Cantabria)

ORGANIZED BY

GONORTE
Grupo Oncológico

08:30 **REGISTRATION**

09:00-09:10 **OPENING**

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander
Dr. Nuria Lainez, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona

09:10-11:15 **SESSION 1. NON-MUSCLE INVASIVE BLADDER CANCER:** ARE NEW TREATMENTS READY FOR PRIME TIME?

Chairs:
Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid
Dr. José Rubio, Urology Department, Hospital Vithas Valencia 9 de Octubre

09:15-09:30 **Clinical Vignette**
Dr. Javier Pizzarello, Urology Department, Hospital Vithas Valencia 9 de Octubre

09:30-09:45 **NMIBC: What do I need to know to understand drug development in this setting?**
Dr. Jozefina Casuscelli, Urology Department, LMU University Hospital, Munich, Germany

09:45-10:00 **New I.O. based treatments are ready for prime time in BCG naïve NMIBC patients**
Dr. Javier Puente, Genitourinary Medical Oncology Department, Hospital Universitario San Carlos, Madrid

10:00-10:15 **New IO. based treatments are not ready for prime time in BCG naïve NMIBC patients**
Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid

10:15-10:30 **Radiotherapy-based treatments as an emerging strategy in HR NMIBC**
Dr. Xavier Maldonado, Radiation Oncology Department, Vall d'Hebron Barcelona Hospital

THURSDAY, OCTOBER 8th

10:30-10:45 **Intravesical drug-delivery systems in BCG-naïve disease: Evidence and limitations**
VIRTUAL
Dr. Bernardo Herrera, Urology Department, Hospital Universitario Virgen de la Victoria, Málaga

10:45-11:15 ***Discussion***

11:15-11:50 COFFEE BREAK

11:50-13:20 SESSION 2. MUSCLE INVASIVE BLADDER CANCER: APPROACHING A CLASSIC DISEASE IN A NEW ERA

Chairs:
Dr. Elena Sevillano, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid
Dr. Jerónimo Barrera, Urological Radiology Department, Hospital Clínico San Carlos, Madrid

11:50-12:05 **Clinical Vignette**
Dr. Joseline M. San Miguel, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

12:05-12:20 **Do I have to convince my radiologist to perform MRI in MIBC? From its role in initial staging to potential biomarker of response**
Dr. Jon Etxano, Radiology Department, Osatek, Osakidetza, Insituto de Investigación Sanitaria Biobizkaia, Barakaldo

12:20-12:35 **Variant histologies in MIBC: Which ones, how often and how much should condition my perioperative treatment selection?**
Dr. Ainara Azueta, Pathology Department, Hospital Universitario Basurto, Bilbao

12:35-12:50 **Do blood or urine biomarkers have any role in guiding perioperative treatment?**
Dr. Yohan Loriot, Medical Oncology Department, Institut Gustave Roussy, Villejuif, France

12:50-13:20 ***Discussion***

13:20-14:05 MEET THE EXPERT SYMPOSIUM | IMFINZI, DRIVING THE CHANGE IN MIBC

Chair: **Dr. Ignacio Durán,** Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

Speakers:
Dr. Javier Puente, Genitourinary Medical Oncology Department, Hospital Universitario San Carlos, Madrid
Dr. Carlos Álvarez, Hospital Universitario Central de Asturias, Oviedo

Sponsored by: AstraZeneca

14:05-15:30 LUNCH BREAK

15:30-17:00 SESSION 3. DEBATING BEST TREATMENT APPROACH IN MUSCLE INVASIVE BLADDER CANCER

Chairs:
Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander
Dr. Mario Álvarez Maestro, Urology Department, Hospital Universitario La Paz, Madrid

15:30–15:50 **Are perioperative ADC combinations the new default strategy?**
Dr. Patrizia Giannatempo, Medical Oncology Department, Instituto Nazionale dei Tumori, Milan, Italy

15:50–16:10 **Perioperative chemotherapy plus checkpoint inhibition: Which and to whom in 2026?**
Dr. Syed A. Hussain, Medical Oncology Department, University of Sheffield, Sheffield Teaching Hospitals NHS Trust, UK

16:10–16:30 **What if I want to preserve my bladder? Current and future bladder sparing strategies in MBIC**
Dr. Terence Friedlander, Genitourinary Medical Oncology, University of California, San Francisco, USA

16:30–17:00 ***Discussion***

THURSDAY, OCTOBER 8th

17:00-17:45 MEET THE EXPERT SYMPOSIUM | TRANSFORMING THE BLADDER CANCER CONTINUUM: FROM PERIOPERATIVE MIBC TO ADVANCED DISEASE

Sponsored by: astellas

17:00–17:05 **Welcome and Introduction**
Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

17:05–17:20 **Keynote Lecture**
EV+P Across Stages and Patient Population
Dr. Terence Friedlander, Genitourinary Medical Oncology, University of California San Francisco, USA

17:20–17:30 **Interactive Expert Panel**

17:30–17:45 **Putting the Patient at the Center: "Translating Evidence into Practice"**
Dr. Alfonso Gómez de Liaño, Medical Oncology Department, Complejo Hospitalario Universitario Insular de Gran Canaria
Dr. Isabel Galante, Genitourinary Medical Oncology Department, Hospital Clinico San Carlos, Madrid

Case 1: Full-Dose Therapy to Achieve Deep Response in La/m UC

Case 2: MIBC cis-ineligible pts with impaired renal function

17:45-18:20 COFFEE BREAK

18:20-19:05 MEET THE EXPERT SYMPOSIUM | ADVANCED DISEASE

Chair:
Dr. María José Juan Fita, Medical Oncology Department, Instituto Valenciano de Oncologia, Valencia

Speakers:
Dr. Petros Grivas, Medical Oncology Department, Genitourinary Cancers Program, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Center

Sponsored by: MSD

19:05-19:15 2024 GO NORTE GRANTS

19:05–19:10 **Mechanisms of resistance to immunotherapy in patients with non-urothelial histological variant metastatic urinary tract tumours (CHESSY PROJECT)**
Dr. Diego Cacho, Medical Oncology Department, Hospital Universitario. Marqués de Valdecilla – IDIVAL, Santander

19:10–19:15 **Prognostic and predictive value of low-density neutrophils in first-line treatment of metastatic renal cell carcinoma with immune checkpoint inhibitors**
Dr. Ibon Gurrutxaga, Medical Oncology Department, Hospital Universitario de Navarra, Pamplona

19:15 -19:45 KEYNOTE LECTURE

Treating Bladder Cancer in 2030: What does the future hold?
Dr. Petros Grivas, Medical Oncology Department, Genitourinary Cancers Program, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Center

19:45-19:50 CLOSING OF THE DAY

20:00 GET TOGETHER COCKTAIL AND DINNER

Venue: Parador de Limpias

FRIDAY, OCTOBER 9th

08:00-08:15 **OPENING**

Dr. Ricardo Fernández, Medical Oncology Department, Hospital Universitario de Cruces, Bilbao

Dr. Carmen Santander, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza

08:15-09:35 SESSION 4. PROSTATE CANCER

Chairs:

Dr. Miguel Ángel Climent, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

Dr. Estefania Linares, Urology Department, Hospital Universitario La Paz, Madrid

08:15-08:30 **The perioperative treatment of high-risk Prostate Cancer in 2026: Where do things stand after PROTEUS?**

Dr. David Lorente, Medical Oncology Department, Instituto Valenciano de Oncologia, Valencia

08:30-08:45 **Advanced hormone sensitive disease: Is the triplet vs doublet debate over?**

Juan Francisco Rodríguez-Moreno, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

08:45-09:00 **Optimizing androgen receptor–targeted therapy in mCRPC in 2026: Present options and near future**

Urbano Anido, Medical Oncology Department, Complexo Hospitalario Universitario de Santiago de Compostela

09:00-09:15 **Positioning PARP Inhibitors in mCRPC: The 2026 Landscape**

Dr. Enrique González-Billalabeitia, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

09:15 - 09:35 ***Discussion***

09:35-10:20 MEET THE EXPERT SYMPOSIUM | mHSPC: THE ADVENT OF PRECISION MEDICINE IN RESPONSE TO AN UNMET MEDICAL NEED

Chair:
Dr. Javier Puente, Genitourinary Medical Oncology Department, Hospital Universitario San Carlos, Madrid

Speakers:
Dr. David Olmos, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid
Dr. David Lorente, Medical Oncology Department, Instituto Valenciano de Oncologia – IVO, Valencia

Sponsored by: Johnson&Johnson

10:20-10:55 COFFEE BREAK

11:00-11:47 MEET THE EXPERT SYMPOSIUM | PLUVICTO IN mCRPC: REDEFINING THE THERAPEUTIC ALGORITHM

Chairs:
Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid
Dr. Iratxe Fernández Tercero, Nuclear Medicine Department, Hospital Universitario de Cruces, Bilbao

Sponsored by: NOVARTIS

11:00-11:03 **Welcome and introduction**

11:03-11:12 **Positioning of Pluvicto in the therapeutic landscape of mCRPC in Spain in 2026**
Dr. Naiara Sagaztibeltza, Medical Oncology Department, Hospital Universitario de Donostia, San Sebastian

11:12-11:21 **Imaging-based selection criteria: The nuclear medicine perspective**
Dr. Zulema Nogareda, Nuclear Medicine Department, Complexo Hospitalario Universitario de Santiago de Compostela

11:21 - 11:35 **Pluvicto: Lessons from clinical experience**
Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona

11:35-11:45 ***Discussion***

11:45-11:47 **Closing Remarks**

11:50-13:05 SESSION 5. HIGH RISK LOCALIZED RENAL CANCER

Chairs:
Dr. Pablo Maroto, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona
Dr. Mario Domínguez, Urology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander

11:50-12:00 **Clinical Vignette**
Dr. Ángel Fernández, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona

12:00-12:15 **Estimating risk after nephrectomy: Are we all in the same page? Are we overtreating?**
Dr. Teresa Alonso, Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid

12:15-12:30 **Reshaping adjuvant treatment in 2026: Is angiogenesis back?**
Dr. Dan Heng, Head, Medical Oncology, Arthur JE Child Comprehensive Cancer Centre, Calgary, Canada

12:30-12:45 **I am in favor of systemic treatment first? Role of neoadjuvant treatment in high risk RCC**
Dr. Axel Bex, Genitourinary Medical Oncologist Department, Amsterdam University Medical Center, The Netherlands Cancer Institute

12:45-13:05 ***Discussion***

13.05-14:10 SESSION 6. ADVANCED RENAL CANCER AND OTHER VLH MEDIATED DISEASES

Chairs:
Dr. Jesús García Donas, Medical Oncology Department, Hospital Universitario HM Sanchinarro - Centro Integral Oncológico Clara Campal HM CIOCC, Madrid
Dr. Xavier García Del Muro, Genitourinary and Sarcoma Unit. Institut Català d'Oncologia, L'Hospitalet de Llobregat

13:05-13:20 **First line mRCC: IO-IO vs IO-TKI: Is the eternal debate over?**
Dr Lisa Pickering, Medical Oncology Department, The Royal Marsden NHS Foundation Trust, London, UK

13:20-13:35 **Sequencing treatments in the advanced setting: Is it clear in 2026?**
Dr. Cristina Suárez, Medical Oncology Department, Vall d'Hebron Barcelona Hospital

13:35-13:50 **Inhibiting HIF in VHL syndrome: A life changer for patients?**
Dr. Guillermo De Velasco, Medical Oncology Department, Hospital 12 de Octubre, Madrid

13:50-14:10 ***Discussion***

14:10-14:40 CLOSING LECTURE

Curing the Incurable? Rethinking long-term disease control in advanced RCC
Dr. Dan Heng, Head, Medical Oncology, Arthur JE Child Comprehensive Cancer Centre, Calgary, Canada

14:40 CLOSING OF THE SYMPOSIUM

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL, Santander
Dr. Ricardo Fernández, Medical Oncology Department, Hospital Universitario de Cruces, Bilbao

V GO NORTE INTERNATIONAL GU DEBATES

SPONSORS

PLATINUM

astellas
AstraZeneca
MSD
NOVARTIS
Johnson&Johnson

SILVER

BAYER
IPSEN
MERCK

BRONZE

Bristol Myers Squibb
EXELIXIS
Pfizer
RECORDATI RARE DISEASES
Roche

AUSPICES

SEOM Sociedad Española de Oncología Médica
SEOM® es una marca registrada. El aval de SEOM no implica la organización ni financiación del evento
+MIR SECCIÓN SEOM
aseica
GUARD CONSORTIUM GU-Alliance for Research and Development

Solicitada la acreditación a la Comisión de Formación Continuada del Sistema Nacional de Salud y de la Consejería de Sanidad de la Comunidad de Cantabria.
La asistencia al curso completo es obligatoria para obtener la acreditación. No recibirán los créditos del sistema acreditador ni estudiantes, ni médicos internos residentes, ya que están excluidos del mismo.

Secretaría técnica
tactics
Barcelona · Madrid 93 451 17 24 info@tacticsmd.net www.tacticsmd.net